Breaking: Why Intracoastal Capital Reported Big Biostar Pharmaceuticals, Inc Position?

Breaking: Why Intracoastal Capital Reported Big Biostar Pharmaceuticals, Inc Position?

The New Intracoastal Capital Holding in Biostar Pharmaceuticals, Inc

Intracoastal Capital filed with the SEC SC 13G form for Biostar Pharmaceuticals, Inc. The form can be accessed here: 000119312516741782. As reported in Intracoastal Capital’s form, the filler as of late owns 2.1% or 56,571 shares of the Health Care–company.

Biostar Pharmaceuticals, Inc stake is a new one for the and it was filed because of activity on October11, 2016. We feel this shows Intracoastal Capital’s positive view for the stock.

Biostar Pharmaceuticals, Inc Institutional Sentiment

Latest Security and Exchange filings show 5 investors own Biostar Pharmaceuticals, Inc. The institutional ownership in Q3 2015 is very low, at 27.40% of the outstanding shares. This is decreased by 55417 the total institutional shares. 723239 were the shares owned by these institutional investors. In total 0 funds opened new Biostar Pharmaceuticals, Inc stakes, 1 increased stakes. There were 2 that closed positions and 1 reduced them.

Morgan Stanley is an institutional investor bullish on Biostar Pharmaceuticals, Inc, owning 167 shares as of Q3 2015 for less than 0.01% of its portfolio. Bank Of America Corp owns 1000 shares or less than 0.01% of its portfolio. NY Renaissance Technologies Llc have less than 0.01% of their stock portfolio for 695570 shares. Further, California Public Employees Retirement System reported stake worth less than 0.01% of its US stock portfolio. The IA Iowa State Bank owns 12384 shares. Biostar Pharmaceuticals, Inc is 0.01% of the manager’s US portfolio.

Business Profile

Biostar Pharmaceuticals, Inc. (Biostar) is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, manufactures and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China). The Company offers over-the-counter (OTC) products and prescription-based pharmaceuticals. The Company’s products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people. The Company’s products include XinAoxing Oleanolic Acid Capsule, Ganwang Compound Paracetamol Capsule, Tianqi Dysmenorrhea Capsule, Compound Paracetamol and Amantadine Hydrochloride Tablets, Deafness Tongqiao pills and Huangyangning Tablets.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

About 634,051 shares traded hands. Biostar Pharmaceuticals Inc (NASDAQ:BSPM) has risen 103.83% since March 16, 2016 and is uptrending. It has outperformed by 98.28% the S&P500.

Biostar Pharmaceuticals, Inc. is a holding company. The company has a market cap of $12.77 million. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, makes and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China). It currently has negative earnings. The Firm offers over-the-counter (OTC) products and prescription pharmaceuticals.

More notable recent Biostar Pharmaceuticals Inc (NASDAQ:BSPM) news were published by: Prnewswire.com which released: “Biostar Pharmaceuticals Completes Previously Announced Registered Direct Financing” on October 18, 2016, also Investorplace.com with their article: “Why Biostar Pharmaceuticals Inc (BSPM), Carbonite Inc (CARB) and Yum! Brands …” published on October 11, 2016, Prnewswire.com published: “Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months …” on August 22, 2016. More interesting news about Biostar Pharmaceuticals Inc (NASDAQ:BSPM) were released by: Benzinga.com and their article: “Crazy Stock Move Of The Day: Biostar Pharmaceuticals” published on June 08, 2016 as well as Benzinga.com‘s news article titled: “18 Biggest Mid-Day Gainers For Tuesday” with publication date: October 18, 2016.

According to Zacks Investment Research, “BioStar Pharmaceuticals, Inc., through its wholly-owned subsidiary, Shaanxi Aoxing Pharmaceutical Co., Ltd., develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company’s most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based over-the-counter products, two prescription-based pharmaceuticals and ten nutrients. The Company has adopted international standards and is in the process of applying for three patents. It also operates an herbal medicine planting base which provides it with many of its needed materials at a significantly lower cost than purchasing from third parties, and eliminates most needs for transportation.”

BSPM Company Profile

Biostar Pharmaceuticals, Inc. (Biostar), incorporated on March 27, 2007, is a holding company. The Company, through its subsidiary, Shaanxi Biostar Biotech, Ltd. (Shaanxi Biostar), and its variable interest entities (VIEs), Shaanxi Aoxing Pharmaceutical Co., Ltd. (Aoxing Pharmaceutical) and Shaanxi Weinan Huaren Pharmaceuticals Ltd. (Shaanxi Weinan), develops, makes and markets pharmaceutical products for various diseases and conditions in the People’s Republic of China (PRC or China). The Firm offers over-the-counter (OTC) products and prescription pharmaceuticals. The Company’s products are derived from medicinal herbs that are either grown at its own facility or purchased from its suppliers. The Company’s products are sold in approximately 30 provinces in the PRC through a network of over 60 distributors and through approximately 230 sales people.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment